Umbralisib
Umbralisib is a dual inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) and casein kinase 1 epsilon (CK1-epsilon) that disrupts B-cell receptor signaling and MYC-driven proliferation in malignant B cells. It has been investigated for the treatment of relapsed or refractory marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and other hematologic malignancies. Its dual kinase inhibition mechanism may provide activity in settings of resistance to other PI3K inhibitors.
Masse moléculaire
571,5000 g/mol
LogP
5,80
TPSA
105,00 Ų
Règle des 5 de Lipinski
Non conforme
Aires thérapeutiques
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
InChI
InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
Molecular Formula
C31H24F3N5O3
HBD / HBA
1 / 10
Liaisons Rotatives
6
Atomes Lourds
42
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Umbralisib is a dual inhibitor of phosphoinositide 3-kinase delta (PI3K-delta) and casein kinase 1 epsilon (CK1-epsilon) that disrupts B-cell receptor signaling and MYC-driven proliferation in malignant B cells. It has been investigated for the treatment of relapsed or refractory marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and other hematologic malignancies. Its dual kinase inhibition mechanism may provide activity in settings of resistance to other PI3K inhibitors.
Yes, Umbralisib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3948730. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 72950888. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="umbralisib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/umbralisib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/umbralisib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/umbralisib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="umbralisib"></drugfyi-drug>